Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 8/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27250180 | 0.92 | CHKA (0.52) | CHKACA2NCF1PRMT6SIGMAR1 | |
| SCHEMBL23269590 | 0.90 | CHKA (0.50) | CHKACA2NCF1PRMT6SIGMAR1 | |
| SCHEMBL11955737 | 0.89 | CHKA (0.48) | CHKACA2NCF1PRMT6SIGMAR1 | |
| SCHEMBL23269592 | 0.87 | CHKA (0.48) | CHKACA2NCF1PRMT6SIGMAR1 | |
| SCHEMBL5507506 | 0.86 | HRH3 (0.48) | PRMT6SIGMAR1 | |
| SCHEMBL5510919 | 0.86 | HRH3 (0.48) | PRMT6SIGMAR1 | |
| SCHEMBL2616296 | 0.84 | PRMT6 (0.48) | CHKACA2NCF1PRMT6SIGMAR1 | |
| SCHEMBL5500538 | 0.83 | HRH3 (0.50) | PRMT6SIGMAR1 | |
| SCHEMBL2056177 | 0.81 | HRH3 (0.52) | CHKACA2NCF1PRMT6 | |
| SCHEMBL19826457 | 0.81 | HRH3 (0.52) | CHKACA2NCF1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911466-B2 | Substituted pyrimidines as vaccine adjuvants | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911466-B2 | Substituted pyrimidines as vaccine adjuvants | TYMS, UMPS, P2RY1 | CHKA 3881/4885CA2 2922/4885NCF1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.